Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

Table 1

Patient demographics and baseline clinical characteristics.

Patient characteristics	Decitabine; ()	Low-dose cytarabine; ()
Age in years (median)	65	62
Sex
Male, (%)	12 (80)	12 (80)
Female, (%)	3 (20)	3 (20)
Duration of symptoms (in months) (median)	2	1
Type of AML
De novo, (%)	13 (86.67)	15 (100)
Secondary, (%)	2 (13.33)	0 (0)
Performance score (ECOG), (%)
1	8 (53.3)	5 (33.3)
2	7 (46.7)	10 (66.7)
Bone marrow blasts, (%)
20–30%	2 (13.33)	8 (53.3)
30–50%	9 (60)	3 (20)
	4 (26.7)	4 (26.7)
Cytogenetics
Unsatisfactory	7 (46.7)	8 (53.3)
Normal karyotype	5 (33.3)	6 (40)
Inv(16)	0 (0)	1 (6.7)
Abnormality of chromosome 8	2 (13.3)	0 (0)
Abnormality of chromosome 7	1 (6.7)	0 (0)